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Abstract
In April 2010, a Medicines and Healthcare Products Regulatory Agency safety alert concerning all metal-on-metal (MOM) hip
replacements recommended measuring chromium and cobalt concentrations when managing patients with painful
prostheses. The need for this review is illustrated by the recent surge in requests for these blood tests from orthopaedic
surgeons following this alert. The aim is to provide guidance to laboratories in assessing these requests and advising
clinicians on interpretation. First, we summarize the basic terminology regarding the types of hip replacements, with emphasis
on the MOM type. Second, we describe the clinical concerns over implant-derived wear debris in the local tissues and distant
sites. Analytical aspects of the measurement of the relevant metal ions and what factors affect the levels measured are
discussed. The application of inductively coupled plasma mass spectrometry techniques to the measurement of these metals
is considered in detail. The biological effects of metal wear products are summarized with local toxicity and systemic
biological effects considered, including carcinogenicity, genotoxicity and systemic toxicity. Clinical cases are used to illustrate
pertinent points.
Ann Clin Biochem 2012; 49: 118–131. DOI: 10.1258/acb.2011.011141
Introduction
Clinical chemistry laboratories in the UK are receiving
increased numbers of requests for blood cobalt (Co) and
chromium (Cr) concentrations because orthopaedic sur-
geons have shown a relationship of concentrations of these
metals to clinical events affecting hip replacements. This
trend has been accelerated by the recent issue by the
Medicines and Healthcare Products Regulatory Agency
(MHRA) in the UK of a Medical Device Alert advising
that all patients with a metal-on-metal (MOM) implant be
followed annually for at least ﬁve years, with blood Cr
and Co measurements when indicated.1
Hip replacements were ﬁrst used in the 1930s by Dr Phillip
Wiles from the Middlesex Hospital in the UK, but it was not
until Sir JohnCharnley’s cementedmetal-on-plastic (MOP) hip
replacements in the 1960s that a design suitable for wide-
spread use was widely available. The ﬁrst implants used a
stainless-steel ball with a Teﬂon cup. The Teﬂon was later
replaced with high-density polyethylene due to the high inci-
dence of osteolysis due to wear debris from the Teﬂon.
Variants of this design have proliferated, and a variety of
materials have been used, including titanium stems and tita-
nium cup shells, different plastics and ceramics.
Every year one million hip replacements are implanted
worldwide and 70,000 in the UK (UK data from the UK
National Joint Registry, www.njrcentre.org.uk). Broadly,
there are three types of implants, classiﬁed according to
their bearing surfaces: MOP, ceramic-on-ceramic and
MOM. Each type has different advantages and disadvan-
tages such as: low wearing; suitability for hip re-surfacing
(involving capping of the femur); and long clinical history.
The most successful type has not yet been determined;
however, there has been a dramatic increase in MOM hips
over the last 10 y.
MOM replacement
The use of MOM hip implants was led by Europe (initially
Germany with small 28-mm diameter femoral head com-
ponents and latterly the UK with large diameter [.36mm]
femoral head components). The latest data from the USA
show that 35% of all hip implants are now MOM. We
have estimated that the total number of MOM implants
that have been implanted is approximately one million,
with the majority over the last 10 y. Many studies have
shown that these have good early (,5 y) and possibly
medium-term (5–10 y) results.
MOM re-surfacings have the advantage that the metal
components can be made thin enough, yet maintain
strength and the ability to bond to bone (often with a
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coating or roughened surface) so that large diameter
femoral head components are feasible. Large diameter
femoral head components are desirable because they offer
increased range of motion (if used with a narrow femoral
neck component), reduced risk of dislocation and the
ability to re-surface or cap the femoral head.
All materials used for hip implants will wear in use.
Particles released from MOP implants, primarily polythene
particles, are typically tens of micrometres in diameter and
can clearly be seen in the surrounding tissue by light
microscopy. They are responsible for osteolysis and
implant loosening in approximately 90% of patients at
10 y postoperatively. MOM implants generate nanometre-
sized metal particles and metal ions at approximately one
trillion per year (one million particles generated per step
times one million steps walked per year).2,3 These 40-nm
particles are not visible using light microscopy, although it
is possible that aggregates may be visible.
The MOM implants have two bearing surfaces of a Co–
Cr–molybdenum (Mo) alloy (most commonly ASTM F754
in the ratio of Co:Cr:Mo of 60:30:7, although other alloys
such as F90, F799, F562 and F1537 may also be used) that
are separated by a thin ﬁlm of synovial ﬂuid when tested
in a hip simulator. However, when used in patients it is
likely that this lubricant ﬁlm is not constant and thick
enough to prevent the surfaces from contacting and generat-
ing wear debris, as evidenced by the reports of a wide range
in blood metal ion concentrations. Typical blood levels of
Co and Cr in patients with unilateral, well functioning
hip implants are 30 and 45 nmol/L (1.7 and 2.3 mg/L),
respectively. However, blood Co concentrations can rise
as high as 6550 nmol/L (387 mg/L) and Cr 3400 nmol/L
(179 mg/L).5 We have recently recorded concentrations of
these metals in ﬂuid surrounding these hips of 400mg/L
of Cr and 22mg/L of Co.
There is an important distinction between MOM hip
replacement and hip re-surfacing. In the former, a
stemmed (femoral) component is used, whereas in the
latter the femur is capped or re-surfaced. Hip re-surfacing
therefore conserves femoral bone by capping the femoral
head rather than removing it. If a later redo/revision oper-
ation is required, then a conventional ‘stemmed’ hip replace-
ment is straightforward on the femoral side and so hip
re-surfacing is favoured for younger patients who are
likely to need more than one hip replacement during their
lives. For the purposes of this review, we have used the
term MOM hip replacement rather than refer to the subset
of hip re-surfacing because it is likely that the most impor-
tant and pertinent clinical problems relate to the bearing
surface.
Since 1996, approximately one million patients have had
MOM hips, with revision due to poor biocompatibility
ranging from 1% to 20% at ﬁve years postoperatively,
depending on the type of prosthesis. The full economic
cost of a revision has been estimated at up to £30,000.
There are many designs of these implants, but all use the
same Co–Cr–Mo alloy, although there are manufacturer
differences in the treatment of the alloy in the manufactur-
ing process. The implants are based on alloys predomi-
nantly manufactured from Co, Cr and Mo, but other
metals such as tungsten, nickel and titanium may also be
present. It is unclear whether these have any effect on the
wear of the implant or on metal release. The lubrication of
the space between the head and the cup by a thin ﬁlm of
synovial ﬂuid6 will remove any released metal from the
joint.
The mechanism of metal release is primarily by wear of
the bearing surfaces, but there may also be an element
of corrosion especially in the shaft. The linear wear rate of
these implants is approximately 5 mm/y,7 but in some
failed implants we have measured wear rates up to
257 mm/y.8 Metals may also be released from implants by
corrosion. This may be caused by the action of body ﬂuids
on the surfaces or by an electrochemical couple being
formed between different metal components.
Local effects of MOM hips
Soft tissue inﬂammatory reactions surrounding MOM
implants have only recently been reported, partly
because imaging techniques such as magnetic resonance
imaging (MRI) previously suffered from artefact due to
the prosthesis. These reactions have been described as
pseudotumours.9,10 Their true prevalence will be
unknown until large-scale MRI screening studies are
carried out. However, studies of small numbers of failures
have found that females are more affected than males,
with one study reporting 14% of young females with
MOM implants affected. Even if the prevalence for the
whole population is much lower, the problem is impor-
tant because it can cause destruction of bone and
muscle, which may be either unreconstructable or leave
the patient with long-term poor function. One type of
MOM implant (the Ultima; Depuy, Warsaw, IN, USA)
was withdrawn by the manufacturers because of this
problem.11,12 The Depuy ASR implant has recently been
withdrawn due to a higher than expected failure rate as
shown in statistics from the National Joint Registry
(NJR, a register of all orthopaedic joint replacements per-
formed in England and Wales).
The British Hip Society in collaboration with the NJR and
the MHRA has recently conducted an audit of this problem
and we await their ﬁndings. Meanwhile, surgeons are
requesting blood Co and Cr concentrations on patients
with MOM implants as a means of understanding how
well the hip is performing in vivo. Research in this area
has increased dramatically. This review summarizes the evi-
dence that has stimulated surgeons to request these tests
and highlights the gaps in understanding that may be
useful to clinical biochemists when understanding the clini-
cal interpretation of blood concentrations of Co and Cr in
patients with MOM hip replacements.
Systemic effects of MOM hip replacements
Cr(VI) is a well-known environmental and occupational car-
cinogen and mutagen, so many reports have focused on the
carcinogenic and mutagenic potential of these implants.
Some reports have shown increased occurrence of some
................................................................................................................................................
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cancers, but the same reports also showed decreased inci-
dence of other cancers in patients with MOM hip replace-
ments.13–15 A recent report has suggested that there may
be an increased incidence of some cancers in rheumatoid
and osteoarthritis patients who have had knee replace-
ments,16 although this increased cancer risk in such patients
may possibly be related to the inﬂammatory disease.17
Concern over the effects of metal ions has prompted
various authorities to examine the potential carcinogenic
effects of MOM hips. Firstly, the UK Government’s
Committee on Mutagenicity of Chemicals in Food,
Consumer Products and the Environment published a state-
ment saying that there was evidence of genetic damage in
patients with all types of MOM and some MOP implants,
but not from stainless steel on polythene implants.18 The
committee concluded that ‘However, it was not possible
to make any deﬁnite conclusions as to which metal ions,
or interactions between metal ions or particulate metals
might be responsible for the observed genotoxicity. . .There
was limited evidence available to suggest a possible inter-
action between chromium and cobalt ions and possible
mutagenicity/DNA damage in vitro but not in vivo. There
was no convincing evidence for metal-speciﬁc effects of
wear debris with regard to potential for clastogenicity or
aneugenicity’. A series of papers from Learmonth and
Case in Bristol19–21 was considered by the committee.
They showed that DNA damage, including aneuploidy
and chromosomal translocations, could be linked to Cr–
Co containing implants, but not to stainless steel-containing
implants. However, the report also concludes that evidence
for an association of these effects with implants is not in
itself evidence of a causal relationship.
Secondly, a review by the National Institute for Health
and Clinical Excellence (NICE) recommended further
research into many of the unknown questions surrounding
metal ions from MOM implants.22 Thirdly, in 2006, the
British Orthopaedic Association organized a national
two-day meeting entitled, ‘Biological Implications of Metal
on Metal Hip Replacements’ which concluded with the
need for more research into this area and has recently con-
ducted a UK-wide audit of all failed MOM implants with
adverse soft tissue changes. Lastly, the US Food and Drug
Administration (FDA) have recommended that the ﬁrst
350 patients of the initial cohort receiving MOM hip
re-surfacing devices should have blood concentrations of
metal ions measured for 10 y postoperatively.23,24 More
recent advice from the FDA25 is more cautious than the
MHRA, ‘At the current time, there is no evidence to
support the need for checking metal ion levels in the
blood or special imaging if patients with MOM hip implants
have none of the signs or symptoms described above and
the orthopaedic surgeon feels the hip is functioning’. No
advice on action limits for metal concentrations is given,
and the advice is to interpret concentrations in the context
of the overall speciﬁc clinical scenario including symptoms,
physical ﬁndings and other diagnostic results.
The British Hip Society has issued revised guidance,26
speciﬁcally aimed at larger diameter implants. The advice
is that the MHRA advice still applies, but that patients
may need to be followed up for the life of the implant.
NICE guidance on the use of MOM hip re-surfacings22
has highlighted the need for further studies on the effects
of metal wear particles from these products, but empha-
sized the safety of these products and general lack of
adverse effects. However, there is a relatively high rate of
revision of these operations, and unexplained pain in
many patients has been related to elevated blood metal con-
centrations and increased blood metal concentrations have
been correlated to the position of the implant.5,27,28 There
have been little published data on appropriate reference
ranges for these metals or the clinical utility of the data.
Measurement of Cr, Co and other metals
Cr and Co are nowadays usually measured in biological
samples by inductively coupled plasma mass spectrometry
(ICPMS), although electrothermal atomization atomic
absorption spectrometry (ETAAS) has also been used, and
was commonly used before the widespread introduction
of ICPMS. The sensitivity of ETAAS for these elements is
limited; for example, in a method for measuring Co in
serum, multiple injections into the graphite tube were
needed to attain the desired sensitivity.29 The large
amount of sample required to obtain the needed sensitivity
will cause a large background absorbance which may have
stretched the capabilities of older instruments. Nevertheless,
the concentrations found in these subjects are well within
the range of ETAAS, and this technique has been used in
several studies.30–32
ICPMS has lower detection limits than ETAAS and is also
capable of simultaneous measurement of Cr and Co, and of
many other elements33,34 and is used in the majority of
studies considered here. Accurate measurements can be
made using either collision/reaction cell quadrupole
ICPMS (Q-ICPMS) or high-resolution ICPMS (HR-ICPMS).
The use of either of these is essential to cope with the inter-
ference on the measurement of 52Cr from 40Ar12C. All of the
available collision/reaction cell instruments are capable of
reducing this interference to acceptable levels while retain-
ing good sensitivity. Although there is in principle interfer-
ence in the measurement of 59Co from ions such as 44Ca14N,
there does not seem to be any signiﬁcant effect of these, and
measurements can be made in standard mode.
High resolution ICPMS, using a double focusing mag-
netic sector mass spectrometer, is available in a few labora-
tories and overcomes the uncertainties of interference
reduction with collision/reaction cells.35–37 The interfer-
ences can usually be completely resolved, but the expense
of the hardware will preclude the use of this technique in
all but a few specialist and research laboratories. Krachler
et al.38 looked in detail at method validation, especially the
use of currently available quality control (QC) samples.
The accuracy of values assigned to their product by one
manufacturer of QC materials was questioned.
The electrochemical technique anode stripping voltame-
try has been used occasionally,39 but is not common. This
is a much more labour-intensive technique and requires a
total acid digestion of the sample before analysis.
Other metals may also be measured. Mo is a component
of the alloy commonly used, but measurement will add
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little diagnostic value. Some other implants may contain
other metals such as iron, nickel, vanadium and titanium
in the alloy used or in other components such as the shell
surrounding the cup and in the shaft. Measurement of Ni
or Ti may be of value in some circumstances where metal
release may be due to corrosion rather than wear at the
bearing surface. Mo and vanadium may also be measured
by Q-ICPMS. The sensitivity for Mo measurement is
limited by the number of isotopes of the element, but it is
readily measured without the need for the use of collision
cell technology. Vanadium suffers from interference from
35Cl16O, but this is readily removed by collision cells.
Nickel may also be measured using collision cell
Q-ICPMS. Titanium measurements by Q-ICPMS are difﬁ-
cult in clinical samples at normal concentrations, although
it is possible to use quadrupole instruments to measure
higher concentrations of titanium. Some workers (Andrew
Taylor, personal communication) have claimed to be able
to measure titanium using optical emission spectroscopy.
Measurement of the major isotope, 48Ti, is interfered with
by 48Ca, which although only 0.19% of total calcium,
would still be in considerable excess over titanium. Other
titanium isotopes, 47Ti and 49Ti, although the abundance
of each is less than 10%, can be measured by HR-ICPMS
using medium resolution settings. Ti measurements are
not practicable using Q-ICPMS.
There are no Certiﬁed Reference Material quality standard
reference materials available, and there is a limited number of
commercial products including both elements at suitable con-
centrations. Until now, most quality assessment materials
and External Quality Assurance programmes have focused
on the industrial exposure requirements for samples. Cr
and Co, in blood, serum and urine, are now included in
the monthly Trace Element Quality Assessment Scheme
(TEQAS) quality assessment scheme in the UK (part of
NEQAS, National External Quality Assessment Service)
organized from the University of Surrey in Guildford and
are also included in the Quebec Multielement Eternal
Quality Assessment Scheme organized by the Institut
National de Sante´ Publique in Quebec, Canada.
Cr and Co can be measured in either blood or serum. For
either it is essential to use trace element-free blood collection
tubes, and suitable tubes with no additives, heparin or
EDTA are available from all blood collection device suppli-
ers. Contamination of samples from standard blood collec-
tion tubes and from needles and syringes has been tested
in the author’s (BS) laboratory and found to be negligible
for most trace elements measured, with the possible
exception of titanium (Table 1). In our laboratory, we have
standardized the protocol using K2EDTA-containing trace
element-free tubes.5 This provides a more stable sample
when tubes are supplied to surgeons in other hospitals for
return to the Implant Retrieval Centre at Imperial College.
For these elements, it is usually recommended that
samples are collected via a Teﬂon catheter, with the ﬁrst
draw through the catheter discarded or used for other
routine testing. In practice, we ﬁnd that the expected con-
centrations in these patients are so much higher than the
reference range in the unexposed population that using a
standard needle will have little impact, although it is still
recommended to take a ﬁrst draw for other testing before
the sample for trace element analysis. Walter et al.40
suggested that most of the Cr and Co is in the serum,
with little associated with erythrocytes.
There have been some reports of urine metal concen-
trations in these patients,36 but urinary metal measurements
are rarely used. Although urine is a non-invasive specimen,
there is potentially a higher variation in urinary excretion
attributable to factors including renal function and urinary
concentration. A random collection is suggested, with the
metal concentration normalized to creatinine concentration.
Synovial ﬂuid metal concentrations can also be
measured,41 and may be of value in some situations. The
ﬂuid surrounding the implant can have a very high concen-
tration of metal. Samples of ﬂuid may be taken by needle
biopsy prior to operation for microbiological testing and
to reduce the ﬂuid pressure in the cavity. A high metal
content in this ﬂuid will be an obvious indicator of wear
in the implant, and has been shown to correlate with
blood concentrations, but does not always add any diagnos-
tic value. Metal analysis of the tissue removed during the
revision operation is also possible, and can complement
the histological ﬁndings, but is largely of research interest.
Blood, serum and urine can be analysed by direct analysis
after simple dilution but synovial ﬂuid and tissue samples
need prior digestion with acid. This is often performed
with a microwave digestion system, but digestion can also
be effectively performed with a heated digestion block.
The need for digestion of synovial ﬂuids is in part due to
the variable nature of the matrix: many of the samples pre-
sented to the author’s (BS) laboratory have a large amount
of solid material, presumably protein aggregates, which
may contain bound metal and thus should not be excluded
from analysis. Fluid samples may also contain intact wear
particles which may not be totally vaporised in the analyti-
cal system.
Table 1 Metal contamination from blood collection system
Cr Co Mo V Ni Ti
Blood 11.6 + 2.9
(0.60+0.03)
15.8+0.3
(0.93+0.02)
36.0+1.1
(3.45+0.11)
2.0+0.1
(0.1+0.005)
22.7+2.5
(1.05+0.12)
Blood þ tube 12.9+1.4
(0.67+0.07)
15.4+0.5
(0.91+0.03)
28.4+5.9
(2.72+0.57)
2.1+0.4
(0.11+0.02)
16.3+1.1
(0.96+0.06)
36.8+11.6
(1.76+0.56)
Blood þ tube
þ needle
15.0+4.4
(0.78+0.23)
14.8+1.1
(0.87+0.06)
28.0+3.6
(2.68+0.35)
2.1+0.3
(0.11+0.02)
19.6+4.6
(1.15+0.27)
49.1+22.8
(2.35+1.07)
Equine blood was analysed by high-resolution inductively coupled plasma mass spectrometry before and after standing in trace element-free blood collection
tubes (BD K2EDTA tubes, BD, Oxford, UK) and after being aspirated into the tube via the Vacutainer needle. All results expressed as nmol/L (mg/L), mean and
standard deviation of six measurements. The Ni assay in the ‘blood’ samples showed high contamination
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Reference concentrations
Unexposed population
Brune et al.42 published a systematic review of 87 papers on
reference concentrations of Cr, in relation to occupational
exposure. The reference range for serum concentrations was
1–3 nmol/L (0.05–0.15mg/L) and for urine was 2–10 nmol/L
(0.1 2 0.5 mg/L), 0.2–1.0 nmol/mmol creatinine. There
have been many studies reporting reference intervals for
Cr and Co in the unexposed population and in occupational
exposure (Table 2). There is a good consensus on the normal
concentration of these metals in blood, serum and urine.
Blood and serum Cr concentrations are less than 5 nmol/L
in many of the studies summarized. This is in line with
the current reference range suggested by the UK Supra
Regional Assay Service (SAS) laboratories of less than 10
nmol/L (0.5 mg/L), which will allow for a degree of
sample contamination. It has generally been accepted that
there is no lower limit, and it is not possible to use serum
or blood concentrations to identify rare cases of Cr
deﬁciency. Similarly, for Co it is generally accepted that
reference concentrations are less than 10 nmol/L (0.51 mg/
L) in both serum and blood.
There are less data available on some of the other metals
mentioned, although there is monitoring of all in occupa-
tionally exposed subjects, usually in urine.
Exposed population
One of the earliest case reports on metal release and
accumulation, from 1980, reported accumulation of metal
in the tissue around the MOM joint, but not around the
contralateral hip, which had an MOP prosthesis.45 High
metalconcentrations were also recorded in several other
tissues and in hair. There is now much interest in quantify-
ing the metal release from implants as a means of identify-
ing the causes of joint failure and possible adverse reactions
to the metal. There is a consensus that increased Cr and Co
concentrations are found in serum, blood and urine. In most
studies there has been no signiﬁcant increase in Mo concen-
trations, but in some cases where the metal is present,
increased nickel and titanium concentrations can be found.
Some of the more recent reports are summarized in
Table 3. The studies suggest that the average concentrations
in patients with pain-free well-functioning implants is 20–
40 nmol/L (1–2mg/L) for both Cr and Co. Most studies
suggest that there is a ‘running-in’ period of up to a year,
with concentrations gradually increasing to a stable level.
In some cases, the running-in period may be followed by
a slight decline. The majority of reported studies have
been on patients with hip replacements, but there have
been some studies on metal release from other orthopaedic
implants and from dental implants. A selection of such
reports on blood or serum and tissue metal concentrations
is listed in Table 4. Increased metal concentrations can be
seen in all of these implants, but do not reach the high con-
centrations found with hip implants.
There have been few studies of metals in tissues, largely
because such studies, looking at tissues other than local to
the implant, have to be at postmortem. Case et al.53 looked
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at patients primarily with stainless steel implants, but also
some Cr–Co implants. Metal was found in lymph nodes,
liver and spleen.54 Similar results from patients with hip
or knee replacements were reported by Urban et al.55 More
widespread dissemination of metals was seen in patients
with a failed implant. In at least one case, chromium phos-
phate particles were detected. Polyethylene particles from
MOP implants were also detected. In both of these
studies, the cause of death was unrelated to the implant.
More recently, Hart et al.56 have studied tissue immediately
surrounding the implant using X-ray synchrotron spec-
troscopy. Widespread deposition of Cr was found, with
few Co particles remaining in the tissues. The Cr was
found to be almost entirely chromium phosphate. Co and
Mo were found as isolated metallic particles.
Causes of increased metal concentrations
Implant-derived metal debris is a consequence of wear, cor-
rosion or both. Modular components have potential for
increased metal release – when compared with one-piece
(monobloc) components such as a hip re-surfacing –
because of the additional wearing surfaces. Clinical
studies relating the mechanism of wear in these implants
to blood metal concentrations and in vitro studies using
hip simulators have been important in deﬁning some of
the factors affecting metal release. The factors shown to be
important include: orientation of the components (particu-
larly the cup); implant design; head size and patient
activity. Khan et al.57,58 measured the rise in serum metal
concentrations after exercise. Signiﬁcant increases in serum
Cr and Co concentrations were found after just one hour
of exercise, with differences between implant types. The
BHR (Birmingham Hip Replacement; Smith & Nephew,
Memphis, TN, USA) and Cormet (Corin, Cirencester, UK)
implants, with a 46.8- or 48-mm diameter head, gave 8.5
and 6.5 times larger increases than Metasul (Zimmer,
Warsaw, IL, USA) implants, with a 28-mm diameter head.
A much lower effect of activity on metal concentrations
was reported by Heisel et al.59 Marginal increases in blood
metal concentrations were found even after treadmill exer-
cise, and no change in normal exercise. In a more recent
study, no correlation was found between activity and
metal concentration.60
There are reports of a strong positive correlation between
cup inclination angle and either wear rate of removed MOM
hips61 or blood metal ion levels.5,62,63 However, there are
confounding variables that may also inﬂuence wear rate;
these can be divided into the following groups: patient
factors (small [,50mm] femoral head size,61,62 gender,
activity); surgical factors (horizontal femoral offset,64 cup
version angle,62 incorrect sizing); and manufacturing
factors (metallurgy and design). Interestingly, among the
ﬁve most used types of MOM hip (BHR, Cormet, ASR,
Metasul, Adept [Finsbury Orthopaedics, Surrey, UK]),
there are no proven statistically signiﬁcant differences in
metal ion release and wear rates despite differences in
metallurgy (e.g. heat-treated versus non-heat-treated) and
design (e.g. amount of hemisphere, clearance between two
bearing surfaces). The angles of inclination and version or
abduction, which deﬁne the orientation of the cup within
the pelvis, are both important. Blood metal concentrations
in patients with an angle of inclination of greater than 558
have been shown to be signiﬁcantly raised. This seems to
be a more important parameter than the duration of the
implant or the manufacturer.
Biological effects of wear products and
metal toxicity: systemic effects
Cr and Co are both essential trace elements. The role of Co
in vitamin B12 is well known. Cr is thought to be essential
for glucose metabolism, and probably helps the binding of
insulin to cell receptors.65 Mo is also essential, but only as
Mo co-factor for sulphite oxidase and xanthine oxidase.66
There is some evidence that nickel67 and vanadium68 may
have some biological function, but this is controversial.
There is no evidence that titanium has any biological role.
However, the concern in this context is the possible toxic
hazard from the metal ions and particles. Toxicity has
most been studied in the metal working industries, but
other toxic effects are also well known.
The effects of the metal wear debris on the local tissues
have dominated the recent debate regarding the use of
MOM hips, but for many years concerns about the potential
biological effects of metal particles have been raised. The
areas of concern are primarily the chemical form of the
metal released from the implant and the metabolic fate of
the metal. The toxicity of Cr and Co has been recognized
as a concern in industrial uses of these metals for many
years.69,70 Fears of carcinogenicity of particles were raised
as early as 1971,71 and a report by the International
Table 4 Reported studies on other joint replacements
Reference Joint Metals Conclusions
47 Knee Cr, Co, Mo Serum Cr and Co increased, no significant increase in Mo
48 Elbow Not measured Tissue deposition of particles and study of recovered implants
49 Spine Serum Ni, blood,
urine Cr
No increase in blood Cr or Ni but increased urine Cr. Urine Cr reduced after removal
of implant
50 Vascular stents Ni, Cr, Mn, Mo In vitro study. Platelet activation by metals may contribute to thrombosis. Diamond
coating reduces metal release
51 Orthodontic implants Ni Ni concentration in saliva increased up to 10 weeks after implantation, then decreased
52 Metal plates and
screws
Al, Ti Al but not Ti accumulates in soft tissue around implant
53 Intramedullary nails Cr, Mo, Ti, Al, V Increased serum concentrations of Cr and Ti
................................................................................................................................................
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Agency for Research on Cancer in 200072 concluded that
alloys containing nickel and Co are possibly carcinogenic
and that there are insufﬁcient data for other more complex
alloys. The current state of knowledge of hazards from
wear metals has recently been reviewed.73
The main concern has been the possibility that Cr is
present as Cr(VI), which is a well-known carcinogen.
There are reports that the Cr released from implants may
be as hexavalent Cr,74 but this is not supported by other
reports. Clinical studies have linked MOM hip replacements
to white blood cell DNA and chromosomal damage and
immunological function disturbances,19–21,75–81 although
as noted previously, epidemiological studies have not
found any evidence for an overall increase in cancer risk.
Co poisoning is known to be associated with cardiomyopa-
thy82,83 and in vitro studies have shown neurotoxic84 effects.
Although not so well known, there have also been reports
of neurotoxicity following treatment of anaemia with cobalt
chloride85 and occupational exposure to Co.86 There have
been a few case reports87–89 linking high Co concentrations
in these patients to neurotoxicity. It seems likely that this
may be a more signiﬁcant risk in orthopaedic patients.
One other aspect of concern, especially now that these
operations are being offered to younger patients, is the poten-
tial for reproductive effects. There are little data published on
the effects of metals on semen, but there are suggestions that
Mo may have adverse effects on semen quality.90 Cr and Co
have not been reported as having any adverse effects.
Brodner et al.91 found that metal concentrations in cord
blood were undetectable, in contrast to maternal blood con-
centrations. However, Novak et al.92 found that metal concen-
trations in blood from neonates whose mothers had implants
were higher than those in controls.
Biological effects of wear products and
metal toxicity: local effects
There is also concern that the metal wear debris causes exag-
gerated periprosthetic tissue inﬂammation surrounding
MOM hips and will cause loosening of the joint,93 bone
loss94 or tissue damage.5 This may be the cause of the high
rate of unexplained pain in failed MOM hips when compared
with MOP hips, 43% and 12% respectively.95 In addition,
these severe inﬂammatory changes have been seen surround-
ing the Ultima MOM hip96 and were responsible for its with-
drawal from the UK health-care market by the MHRA. The
large mass that can develop surrounding the tissue, some-
times referred to as a ‘pseudotumour’, can be readily visual-
ized by MRI scans.9,10 There is also a typical inﬂammatory
response in the tissue which has been termed ALVAL:
aseptic lymphocytic vasculitis-associated lesion.97 There are
no published data suggesting that measurement of circulating
concentrations of inﬂammatory markers, such as serum
C-reactive protein, has any diagnostic value.
Hur et al.98 published a short study of ﬁve patients with a
MOM implant who had renal failure. The patients with
renal failure had higher Co concentrations than patients
with normal renal function, but the Cr concentrations
were similar. It was not stated whether the patients were
dialysis-dependant, although one patient underwent renal
transplantation, and concentrations in comparative patients
with renal failure but without a hip replacement or other
surgical implant were not given.
Clinical value of metal measurements
It is possible to use the published data to propose acceptable
blood concentrations of Cr and Co in these patients and to
deﬁne action levels to determine the need for further clinical
investigation and action. This is the approach taken in deﬁn-
ing the action concentrations in the recent MHRA safety alert.
The level of 7mg/L Cr or Co (135 nmol/L Cr or 119 nmol/L
Co) was derived from the data in a recent study75,76 and
comes from the statistical extreme outlier deﬁnition of third
quartile (Q3)þ2interquartile range. The range of concen-
trations found in this study is shown in Table 5.
A potential use of blood metal ion concentrations is to
identify those patients who may go on to develop further
problems. High concentrations in an asymptomatic patient
may be an indication of increased wear which may indicate
need for an early revision before tissue necrosis becomes a
problem. Lower concentrations can be used to reassure non-
symptomatic patients and minimize the need for long-term
follow-up.
Clinical case examples
Case 1 – Silent osteolysis in a 29-year-old woman
A 29-year-old woman presented with sudden onset of
left hip pain and inability to bear weight following a low--
energy wakeboarding incident. She had had a pelvic osteot-
omy in 2000 and subsequently a Birmingham Hip
Resurfacing (Smith and Nephew) in 2001. In 2006, a plain
antero-posterior (AP) radiograph of the pelvis showed evi-
dence of neck narrowing (Figure 1). There appears to be rar-
iﬁcation and reduced bone density with thinning of the
iliopectineal cortical outline medially. Blood metal ion
Table 5 Median and interquartile range for chromium and cobalt in different patient groups (data from refs75,76)
MOP (n 33) COC (n 25) Unilateral MOM (n 88) Bilateral MOM (n 18)
Age in years (range) 64 (55–67) 59 (54–60) 56 (51–61) 56 (51–61)
Months after surgery 25 (18–20) 25 (20–33) 43 (37–52) 29 (24–34)
Cobalt (nmol/L, mg/L) 7.5 (5.4–12.7) 2.0 (1.7–4.2) 29 (21.9–39.5) 41.5 (26.5–73)
0.44 (0.32–0.75) 0.21 (0.17–0.25) 1.71 (1.29–2.33) 2.45 (1.56–4.30)
Chromium (nmol/L, mg/L) 12.5 (4.0–21.1) 6.1 (4.6–8.7) 44.8 (34.4–56) 45.2 (32.7–64.6)
0.65 (0.21–1.10) 0.32 (0.24–0.45) 2.33 (1.79–2.91) 2.35 (1.70–3.36)
MOP, metal-on-plastic, COC, ceramic-on-ceramic, MOM, metal-on-metal
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levels were Co 621 nmol/L (36.6 mg/L) and Cr 730 nmol/L
(38 mg/L). Figure 2 shows an AP radiograph from 2007
immediately after her wakeboarding accident. There is a
fracture of her pelvis adjacent to the left hip re-surfacing.
Cup inclination measured 558 with uncovering of head
and edge loading. Component head size and outer shell
diameter were 42 and 48mm, respectively. Note the right
hip dysplasia with evidence of previous periacetabular
osteotomy and a gracile femur. Metal concentrations
were also measured in synovial ﬂuid: Cr 228,000 nmol/L
(11,850 mg/L) and Co 12,600 nmol/L (745 mg/L). Figure 3
shows an AP radiograph postﬁxation and total hip
replacement.
The clinical ‘metal ion’ questions raised by this case are:
did blood metal ion levels return to normal following revi-
sion? This was very important to the psychological
wellbeing of the patient who was of reproductive age,
planning a family and had read about carcinogenicity fol-
lowing MOM hips. Subsequent metal concentrations were
Cr 199 nmol/L (10.3 mg/L) and Co 28 nmol/L (1.7 mg/L) in
October 2008 and Cr 91 nmol/L (4.7mg/L) and Co 13 nmol/L
(0.8 mg/L) in October 2009. As in other patients with metal-
losis, Cr concentrations can remain elevated after revision,
while Co concentrations can fall relatively quickly.
Case 2 – Silent osteolysis and imminent acetabular
fracture and high metal ion levels in a 65-year-old man
Figure 4 shows an AP radiograph from a 65-year-old man
who presented with a painful right MOM hip re-surfacing
(Birmingham Hip Resurfacing, Smith and Nephew) ﬁve
years postoperatively. The femoral component was loose
Figure 1 Case 1. Plain antero-posterior radiograph of the pelvis showed evi-
dence of neck narrowing. There appears to be rarification and reduced bone
density with thinning of the iliopectineal cortical outline medially
Figure 2 Case 1. Antero-posterior radiograph from 2007 immediately after
her wakeboarding accident. There is a fracture of her pelvis adjacent to the
left hip re-surfacing. There appears to be rarification and reduced bone
density with thinning of the iliopectineal cortical outline medially
Figure 3 Case 1. Antero-posterior radiograph postfixation and total hip
replacement
Figure 4 Case 2. Antero-posterior radiograph from a 65-year-old man who
presented with a painful right metal-on-metal hip re-surfacing five years post-
operatively. The femoral component is loose and the acetabular fracture was
so thin that fracture was imminent
................................................................................................................................................
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and the acetabular bone was so thin that fracture was
imminent. High blood metal ions were recorded (Cr
698 nmol/L [36.3 mg/L] and Co 1212 nmol/L [71.4 mg/L]),
and may have predicted such severe osteolysis if they
had been measured prior to this. A postrevision
AP radiograph (Figure 5) shows the extent of the recon-
struction needed to stabilize the bony defects found at
operation. By six months postrevision, he was able to
return to sailing the Atlantic Ocean. A series of later pre-
and postoperative measurements of blood Co and Cr
revealed a dramatic rate of decay for Co levels and a
slower rate for Cr (Figure 6). The blood metal concen-
trations had increased in the period following the initial
outpatient appointment.
The clinical ‘metal ion’ questions posed by this case are: is
the other hip at risk? Did the levels of metal ions return to
that of a typical unilateral MOM hip? Was the loss of
bone caused by local metal ion poisoning? We once again
show that the Co concentration falls to normal concen-
trations much faster than does Cr concentration. There can
be no direct proof in an individual case that the loss of
bone density is directly caused by metallosis, but we
suggest that it is a reasonable assumption that this is the case.
Case 3 – Silent muscle necrosis with very high metal
ions and rapid deterioration requiring revision and
inability to reconstruct muscle
A 54-year-old lady attended a research clinic with a good
hip function score and very high blood metal ion concen-
trations with an ASR hip re-surfacing (DePuy, Leeds, UK).
Blood Cr concentration was 2700 nmol/L (140 mg/L) and
Co concentration was 6551 nmol/L (386.5 mg/L). An AP
radiograph is shown in Figure 7. Two years later her hip
function deteriorated dramatically. This might have been
better predicted from the high metal ion concentrations.
Three-dimensional computed tomography measurement
(Figure 8) revealed cup angles of 708 inclination (the
optimum is 458 because angles higher than this cause
edge loading and high rates of wear of the hip) and 498 ante-
version (the optimum is between 5 and 258, depending on
the femoral version). Metal artefact reduction sequence
MRI99 revealed a large trochanteric bursa (Figure 9) with
evidence of nodularity within the bursal sac and an irregu-
lar wall. A large amount of black ﬂuid surrounded the hip
at revision operation. Synovial ﬂuid analysis showed Cr
Figure 5 Case 2. Antero-posteriorradiograph showing the extent of the
reconstruction needed to stabilize the bony defects found at operation
Figure 6 Case 2. Pre- and postoperative changes in blood chromium and cobalt concentrations
Figure 7 Case 3. Antero-posterior radiograph from a 54-year-old lady who
attended a research clinic. She had a good hip function score and very high
blood metal ion concentrations
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concentration 5063 mmol/L (263.3 mg/L) and Co concen-
tration 207.1 mmol/L (12.2 mg/L). Analysis of the explanted
hip revealed a wear rate that was 100 times greater than pre-
dicted by hip simulator studies.
The clinical ‘metal ion’ questions raised by this case are:
the patient wanted to know why this had happened?
Did the metal ion levels return to normal? Could other
patients be spared the muscle destruction if earlier
Figure 8 Case 3. Three-dimensional computed tomography (3D CT) measurement showing cup angles of 708 and 498 anteversion
Figure 9 Case 3. Metal artefact reduction sequence magnetic resonance imaging revealed a large trochanteric bursa with evidence of nodularity within the
bursal sac and an irregular wall
Figure 10 Case 3. Pre- and postoperative changes in blood chromium and cobalt concentrations. Preop, preoperative; Postop, postoperative
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intervention is taken? The change in blood metal concen-
trations following the operation is shown in Figure 10. The
blood Co concentration showed a signiﬁcant fall in the
weeks before the revision surgery, probably due to her
reduced activity as a result of the pain from the joint.
There is an immediate and ongoing fall in metal concen-
trations postsurgery, although concentrations remained
very high for a considerable time after the operation, and
Cr continues to remain high more than 12 months later.
We are continuing to monitor metal concentrations to see
if there is an eventual fall to ‘acceptable’ levels. The con-
clusion is that there remains a slow release pool of Cr, poss-
ibly with the capsular tissues. There appears to be no toxic
effect of this very high metal concentration. The very high
metal concentrations seen preoperatively are a clear indi-
cation of high wear in the joint. The patient was reviewed
for a year before the revision operation. It may be that the
ﬁnal tissue damage may have been less severe had the oper-
ation been performed sooner during this period. This high-
lights the need to take clinical action when raised metal
concentrations are seen in these patients, even if there is as
yet no pain.
Conclusions
Increased circulating concentrations of Cr and Co can be
used to monitor wear in MOM hip replacements. These
operations are very successful but a minority of patients
suffer wear in the joint, which will be reﬂected in increased
metal concentrations. These may be used in conjunction
with radiological and clinical assessments to inform the
decision about revision of the original operation. The
recent MHRA safety alert will serve to bring this potential
problem to the attention of all concerned and expedite the
clinical decision before major clinical problems arise.
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